First-line Dasatinib Plus Conventional Chemotherapy in Adults With Newly Diagnosed Ph-Positive ALL

Phase 2 Completed 51 enrolled The Catholic University of Korea

NaSingle-groupOpen-labelTreatment

Summary

The main aim of the present study is to evaluate the clinical efficacy of first-line dasatinib plus conventional chemotherapy for newly diagnosed Ph-positive acute lymphoblastic leukemia. In this study, the investigators will analyze the clinical outcomes for entire patient population as well as those for transplants, respectively. In addition, the results of this study will be compared to those of the investigators current study (imatinib plus conventional chemotherapy). The safety of this treatment will also be studied.

Timeline

Start: 2010-03
Primary completion: 2014-04
Completion: 2015-04

Publications

Yoon JH, Yhim HY, Kwak JY, Ahn JS, Yang DH, Lee JJ, Kim SJ, Kim JS, Park SJ, Choi CW, Eom HS, Park SK, Choi SY, Kim SH, Kim DW, Lee S. Minimal residual disease-based effect and long-term outcome of first-line dasatinib combined with chemotherapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia. Ann Oncol. 2016 Jun;27(6):1081-1088. doi: 10.1093/annonc/mdw123. Epub 2016 Mar 6.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	dasatinib anhydrous	Small molecule	100 mg	Oral
Background	Cyclophosphamide	Other / unclassified	300 mg/m2	Intravenous
Background	Cytarabine	Small molecule	2 g	Intravenous
Background	Daunorubicin	Small molecule	45 mg/m2	Intravenous
Background	Dexamethasone	Small molecule	40 mg	Intravenous
Background	Mitoxantrone	Small molecule	12 mg/m2	Intravenous
Background	Vincristine	Small molecule	1.4 mg/m2	Intravenous

First-line Dasatinib Plus Conventional Chemotherapy in Adults With Newly Diagnosed Ph-Positive ALL

Summary

Timeline

Publications

Drugs

Indications